Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity
Chemical Biology & Drug Design · 2023-03 · 101 (3) · 568-580
DOI: 10.1111/cbdd.14145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 21.09.2022. Verfasst von Chaochun Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Environment and Life, Beijing University of Technology, Beijing, China. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
In our research on novel anticancer agents, a series of N 6 ‐hydrazone purine derivatives were designed and synthesized by analysis of a pharmacophore model for ATP‐competitive inhibitors. The activities screening results showed that N 6 ‐hydrazone purine derivatives 21 and 26 not only showed potential antiproliferative activity against the A549 and MCF‐7 cell lines comparable to Vandetanib as a positive control but also had moderate antiplatelet aggregation activity. In order to investigate the possible targets, a molecular docking study was carried out on the fourteen kinases associated with anticancer and antiplatelet aggregation activities. The results indicated that compounds 21 and 26 had the potential activity to target VEGFR‐2, PI3Kα, EGFR, and HER2 kinases. The inhibition of the kinases assay showed that compound 26 could target VEGFR‐2, PI3Kα, and EGFR (IC 50 = 0.822, 3.040 and 6.625 μM). All results indicated that compound 26 will be an encouraging framework as potential new multi‐target anticancer agent with potential antiplatelet aggregation activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Environment and Life, Beijing University of Technology, Beijing, China.
- Beijing Tide Pharmaceutical Co., Ltd, Beijing, China.
ORCID-Profile: Hong Yan
Förderung
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wei, C., Zhou, L., Yang, Y., Niu, L., & Yan, H. (2023). Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity. Chemical Biology & Drug Design, 101(3), 568-580. https://doi.org/10.1111/cbdd.14145
Vancouver
Wei C, Zhou L, Yang Y, Niu L, Yan H. Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity. Chemical Biology & Drug Design. 2023;101(3):568-580. doi:10.1111/cbdd.14145
BibTeX
@article{Wei2023,
author = {Wei, Chaochun and Zhou, Liying and Yang, Yifan and Niu, Lexuan and Yan, Hong},
title = {Design, synthesis, and anticancer evaluation of N 6 ‐hydrazone purine derivatives with potential antiplatelet aggregation activity},
journal = {Chemical Biology & Drug Design},
year = {2023},
volume = {101},
number = {3},
pages = {568--580},
doi = {10.1111/cbdd.14145}
}
EUVIMED